DermTech Appoints Two New Board Members

July 18, 2022

Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. joined the Company’s board of directors.

DermTech, Inc. appointed Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company’s board of directors, effective July 18,2022. 

These appointments expand DermTech’s board of directors to eight members.

“We are excited to welcome Kirk and Mark as new independent directors,” says Matt Posard, DermTech’s chairman, in a news release. “They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth companies will provide our board with valuable insights as we look ahead to important operating milestones.”

Dr. Malloy has spent more than 25 years in key leadership positions with Illumina, Inc., Biosite Inc. and QIAGEN Inc., and most recently served as the chief executive officer of Verogen, Inc., from August 2017 to August 2018 after founding the company and securing initial funding. Dr. Malloy is currently founder and principal at BioAdvisors, LLC, where he provides strategic consulting services to life science, diagnostics, and genomics companies. Prior to founding BioAdvisors in April 2016, he was at Illumina, Inc. from 2002 to 2016, most recently as senior vice president and general manager of Life Sciences and Applied Markets from January 2014 to April 2016. From May 2005 to December 2013, he served as vice president of Global Customer Solutions; he was also vice president of Global Quality from December 2005 to May 2007. Dr. Malloy joined Illumina in 2002 as senior director of Global Customer Solutions. Before Illumina, he held various commercial leadership positions at Biosite Inc. and QIAGEN Inc. Dr. Malloy currently serves as a director for NanoString Technologies, Inc. (NASDAQ: NSTG), as chairman of the board for cancer diagnostics company, Tagomics, and is a director for several private genomics tools companies. Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University.

“I am impressed with DermTech’s progress as it works to meaningfully improve the standard of care in dermatology with precision genomics,” says Dr. Malloy. “The Company is reshaping the dermatology landscape by bringing non-invasive solutions to patients that need better options. I am thrilled to join a passionate board of directors with a unified vision.”

Mr. Capone is an accomplished life sciences executive, most recently serving as president and chief executive officer of Myriad Genetics. During his 17-year tenure, Myriad Genetics developed and launched more than a dozen reimbursed molecular diagnostics achieving total annual revenues of more than $800 million. Prior to Myriad, he spent 17-years at Eli Lilly and Company in various leadership positions. Mr. Capone currently serves as chief executive officer of Precision Medicine Advisors, LLC, and is a non-executive board member of Abcam plc and Owlstone Medical. He received a B.S. in Chemical Engineering from Penn State University graduating with highest distinction, and his M.S. in Chemical Engineering (biotechnology emphasis) and Management from Massachusetts Institute of Technology.

“DermTech brings non-invasive precision dermatology solutions to patients that need better options,” says Mr. Capone. “The Company’s robust product pipeline addresses large markets in skin disease including cancer. I am honored to join the board and support DermTech’s mission to improve the lives of millions with individualized care.”

About DermTech

DermTech provides genomic analysis of skin samples collected non-invasively using its Smart Stickers. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. 

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free